IL-1RA autoantibodies: insights into mechanisms and associated diseases

Am J Transl Res. 2024 Feb 15;16(2):374-386. doi: 10.62347/NTVU5728. eCollection 2024.ABSTRACTThe association of neutralizing autoantibodies targeting interleukin-1 receptor antagonist (IL-1RA) with multisystem inflammatory syndrome, IgG4-related disease, and vaccine-related myocarditis is increasingly recognized. The detection of IL-1RA autoantibodies can be notably affected by the techniques and methods employed. Two categories of assays are available: solid-phase immunoassays, which detect binding of IL-1RA autoantibodies, and functional IL-1 signaling reporter cell assays, which offer greater specificity by determining whether circulating autoantibodies can impede interleukin (IL)-1β signal transduction pathways. It is as yet unclear why only a minority of individuals produce pathogenic anti-IL-1RA autoantibodies in response to coronavirus disease 2019 (COVID19) or vaccination. This review article discusses our current knowledge of the process of IL-1RA autoantibody generation, the underlying pathogenesis, detection, and potential treatment strategies for associated diseases.PMID:38463591 | PMC:PMC10918145 | DOI:10.62347/NTVU5728
Source: American Journal of Translational Research - Category: Research Authors: Source Type: research